Reprogramming CD22 CAR-T cells in vivo Using CD8-Targeted mRNA-LNPs to Treat Hematological Malignancies - PubMed
7 days ago
- #CAR-T therapy
- #mRNA-LNPs
- #hematologic malignancies
- Ex vivo CAR-T cell therapy is effective for B cell hematologic malignancies but has limitations like personal manufacturing needs and barriers such as toxicity and tumor antigen escape.
- A novel delivery platform uses targeted lipid nanoparticles (LNPs) to reprogram human T cells in vivo, overcoming many current therapy barriers.
- The platform employs a NANOBODY®-based targeting moiety to deliver mRNA encoding a CD22 CAR specifically to CD8+ cells, enabling transient CAR expression.
- Targeted LNPs allow for repeated dosing and minimize off-target mRNA expression.
- In a humanized Nalm6 tumor mouse model, in vivo reprogrammed T cells inhibited tumor growth.
- The platform is flexible, broadly applicable for hematologic malignancies, and adaptable to other diseases.